IL1RL1 Protein (AA 19-328)

Catalog No. ABIN2666553

This Recombinant IL1RL1 protein is expressed in HEK-293 Cells.

Quick Overview for IL1RL1 Protein (AA 19-328) (ABIN2666553)

Target: IL1RL1 (Interleukin 1 Receptor-Like 1 (IL1RL1))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 19-328

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 = 15 - 90 ng/ml, corresponding to a specific activity of 1.1 - 6.6 x 104 units/mg , as determined by inhibition of D10.G4.1 cell proliferation induced by IL-33.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20 °C to -70 °C. Stock solutions can also be prepared at 50 - 100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in 10 mM NaHPO4, 0.3M NaCl, and pH 7.2.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Target Details

Target: IL1RL1 (Interleukin 1 Receptor-Like 1 (IL1RL1))

Alternative Name: IL-1RL1

Background: IL-1RL1/ST2 was initially identified in stimulated Balc3T3 cells and is encoded by the IL-1RL1 gene that produces different isoforms by alternative splicing. In humans, four isoforms have been described: a membrane attached ST2L isoform and a soluble protein (sST2/ IL1RL-a) that lacks the transmembrane and cytoplasmic domains, which acts as a natural antagonist of IL-33. The other splice variants are ST2V and ST2LV. ST2V lacks the third immunoglobulin motif and C-terminal portion of ST2 and is mainly present in the gut whereas ST2LV does not have the transmembrane domain. The membrane isoform of ST2L (IL-1RL1) associates with IL-1 receptor accessory proteins (IL-1RAcP) to form the IL-33R. The interaction of IL-33 to its receptor activates NF-kB and MAP kinases and induces Th2 cytokines from in vitro polarized Th2 cells. In vivo, IL-33 promotes the expression of IL-4, IL-5, and IL-13. IL-33 acts as an inflammatory cytokine in Th2-type immune responses during asthma and atopic dermatitis. It is host-protective against helminth infections and reduces atherosclerosis by promoting Th2-type immune responses. Human aortic, coronary artery, and heart microvascular endothelial cells express mRNA for ST2L and sST2 isoforms, acting as a source for sST2 proteins. In fact, sST2 is considered as a prognostic biomarker in myocardial infarction and heart failure. In addition, sST2 has been associated with other human diseases including asthma with acute exacerbation, eosinophilic pneumonia, sepsis and trauma, and exacerbated idiopathic pulmonary fibrosis.

Molecular Weight: The 550 amino acid recombinant protein has a predicted molecular mass of approximately 62 kDa. The DTT-reduced and non-reduced protein migrate approximately at 100 kDa and 200 kDa by SDS-PAGE. The predicted N-terminal amino acid is Lys.